Page 1

KRONOS BIO Kronos Bio Reports Recent Business Progress and Third - Quarter Financial Results November 9 , 2021 Company today announces progression of two discovery programs within its pipeline Highlights from the quarter include presentation of preclinical data on the company's CDK9 inhibitor KB - 0742 at AACR - NCI - EORTC meeting in October ; Kronos Bio remains on track to report interim data from ongoing Phase 1/2 trial of KB - 0742 by year end $ 398.4 million in cash , cash equivalents and investments as of September 30 , 2021 SAN MATEO , Calif . and CAMBRIDGE , Mass . , Nov. 09 , 2021 ( GLOBE NEWSWIRE ) -- Kronos Bio , Inc. ( Nasdaq : KRON ) , a company dedicated to transforming the lives of those affected by cancer , today reported recent business progress and third - quarter financial results . " As we approach the end of the year , we look forward to reporting interim data from the ongoing Phase 1/2 study of our internally discovered CDK9 inhibitor , KB - 0742 , capping off a year of significant progress , " said Norbert Bischofberger , Ph.D. , president and chief executive officer of Kronos Bio . " In addition to continued execution across our clinical stage programs , I am also pleased with the progress we are making with our pipeline particularly the addition of two new discovery programs , which underscore the capabilities of our product engine . " Pipeline Progress Kronos Bio today announced it has initiated two new discovery programs , each focused on a distinct target or node identified through the company's research and mapping of the MYC and AR transcriptional regulatory networks ( TRNs ) . • Target 1 : MYC TRN . Dysregulation of the MYC TRN is a hallmark of cancer and occurs in a large percentage of cancers . The company's existing development candidate , KB - 0742 , targets CDK9 and is being evaluated in a Phase 1/2 clinical study . KB - 0742 is intended to target MYC dysregulation in the context of MYC genomic amplification , which occurs in 30 % of all solid tumors . The new Target 1 program is aimed at modulating a protein - protein interaction in the MYC TRN with the objective of treating additional MYC - dysregulated cancers beyond those targeted by KB - 0742 . • Target 2 : AR TRN . Dysregulation of the AR ( androgen receptor ) TRN is a primary driver of prostate cancer . Although therapies that directly inhibit the androgen receptor already exist , many patients with prostate cancer ultimately develop resistance to these therapies and patients with castration - resistant prostate cancer ( CRPC ) have a particularly poor prognosis . This new program aims to overcome resistance to current therapies by targeting an AR cofactor that selectively modulates the AR TRN in the context of CRPC . • The company anticipates identifying a lead candidate and submitting an Investigational New Drug ( IND ) application out of one of its discovery programs in 2023 . Additionally , Kronos Bio yesterday announced a multi - year collaboration with Tempus , a leader in artificial intelligence and precision medicine . The agreement will provide Kronos Bio with access to real - world patient genomic and transcriptomic data and data analytics tools , with the goal of accelerating the development of the company's current and future clinical portfolio . Third - Quarter Company Highlights • Kronos Bio presented preclinical data characterizing the pharmacokinetic ( PK ) and pharmacodynamic ( PD ) profile of KB - 0742 in a poster at the AACR - NCI - EORTC Virtual International Conference on Molecular Targets and Cancer Therapeutics in October 2021. These data build on results first shared at the American Association for Cancer Research meeting earlier this year . The new data demonstrated a favorable preclinical PK profile and human PK projection that support the intermittent dosing schedule for patients in the Phase 1/2 study . • The U.S. Food and Drug Administration cleared the company's IND for lanraplenib , a next - generation spleen tyrosine kinase ( SYK ) inhibitor . This allows Kronos Bio to proceed with its planned Phase 1b / 2 clinical trial of the compound in patients with relapsed or refractory FLT3 - mutated acute myeloid leukemia ( AML ) in combination with gilteritinib . Upcoming Milestones • The company plans to report interim safety , PK and PD data in Q4 2021 from the ongoing dose escalation phase of its Phase 1/2 clinical trial of KB - 0742 , which is being developed to treat MYC - amplified or over - expressing solid tumors . • Kronos Bio remains on track to dose the first patient in its planned Phase 3 clinical trial of entospletinib before the end of the year , with a data readout expected in the second half of 2023. This trial will assess measurable residual disease ( MRD ) negative complete response as the primary endpoint to support potential accelerated approval in patients newly diagnosed with NPM1 - mutated AML and eligible for intensive induction chemotherapy . • The company expects to dose the first patient in the first of two planned Phase 1b / 2 clinical trials of lanraplenib in the first quarter of 2022. This first trial will evaluate lanraplenib in patients with relapsed or refractory FLT3 - mutated AML . • Kronos Bio plans to initiate a second Phase 1b / 2 clinical trial of lanraplenib , in combination with venetoclax / azacitidine in